Keith Neeves
Concepts (374)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Platelets | 32 | 2026 | 379 | 5.340 |
Why?
| | Blood Coagulation | 22 | 2026 | 274 | 3.950 |
Why?
| | Microfluidic Analytical Techniques | 19 | 2018 | 79 | 3.620 |
Why?
| | Thrombosis | 22 | 2026 | 400 | 3.540 |
Why?
| | Fibrin | 10 | 2024 | 84 | 2.310 |
Why?
| | Platelet Aggregation | 15 | 2026 | 99 | 2.050 |
Why?
| | Hemostasis | 8 | 2021 | 98 | 2.050 |
Why?
| | Hemophilia A | 5 | 2024 | 148 | 1.860 |
Why?
| | Thrombin | 7 | 2026 | 172 | 1.730 |
Why?
| | Platelet Activation | 9 | 2026 | 99 | 1.450 |
Why?
| | Colloids | 4 | 2020 | 59 | 1.320 |
Why?
| | Fibrinolysis | 4 | 2021 | 164 | 1.280 |
Why?
| | Drug Delivery Systems | 6 | 2022 | 381 | 1.180 |
Why?
| | Microfluidics | 10 | 2020 | 61 | 1.150 |
Why?
| | Tissue Plasminogen Activator | 3 | 2024 | 248 | 1.090 |
Why?
| | Platelet Adhesiveness | 7 | 2026 | 14 | 1.080 |
Why?
| | Vascular System Injuries | 3 | 2017 | 81 | 0.940 |
Why?
| | Factor VIIa | 2 | 2024 | 43 | 0.920 |
Why?
| | Lab-On-A-Chip Devices | 5 | 2021 | 61 | 0.880 |
Why?
| | Collagen | 9 | 2019 | 457 | 0.860 |
Why?
| | Blood Platelet Disorders | 2 | 2023 | 10 | 0.840 |
Why?
| | von Willebrand Factor | 6 | 2026 | 85 | 0.810 |
Why?
| | Magnetic Fields | 5 | 2022 | 24 | 0.800 |
Why?
| | Biomimetics | 2 | 2014 | 41 | 0.790 |
Why?
| | Models, Biological | 9 | 2026 | 1764 | 0.770 |
Why?
| | Plasminogen | 2 | 2024 | 27 | 0.750 |
Why?
| | Nanoparticles | 4 | 2019 | 517 | 0.660 |
Why?
| | Erythrocytes | 3 | 2018 | 749 | 0.660 |
Why?
| | Venous Thrombosis | 2 | 2026 | 196 | 0.650 |
Why?
| | Platelet Membrane Glycoproteins | 3 | 2018 | 31 | 0.640 |
Why?
| | Nanomedicine | 2 | 2022 | 47 | 0.620 |
Why?
| | Rheology | 3 | 2016 | 94 | 0.620 |
Why?
| | Thromboplastin | 7 | 2018 | 67 | 0.620 |
Why?
| | Plasminogen Activators | 1 | 2019 | 7 | 0.610 |
Why?
| | Fibrinolysin | 1 | 2019 | 19 | 0.600 |
Why?
| | Thrombolytic Therapy | 2 | 2024 | 164 | 0.600 |
Why?
| | Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 94 | 0.600 |
Why?
| | Antifibrinolytic Agents | 1 | 2019 | 64 | 0.560 |
Why?
| | Tranexamic Acid | 1 | 2019 | 59 | 0.560 |
Why?
| | Drug Carriers | 1 | 2019 | 136 | 0.560 |
Why?
| | Factor V | 3 | 2026 | 26 | 0.550 |
Why?
| | Cesium | 1 | 2018 | 20 | 0.550 |
Why?
| | Venous Valves | 1 | 2018 | 1 | 0.550 |
Why?
| | Regional Blood Flow | 4 | 2017 | 514 | 0.540 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2024 | 992 | 0.530 |
Why?
| | Fibrinogen | 3 | 2017 | 180 | 0.500 |
Why?
| | Torpor | 1 | 2017 | 19 | 0.500 |
Why?
| | Genetic Diseases, Inborn | 1 | 2017 | 45 | 0.500 |
Why?
| | Fibrinolytic Agents | 1 | 2019 | 297 | 0.490 |
Why?
| | Factor VIII | 4 | 2024 | 106 | 0.480 |
Why?
| | Pharmaceutical Preparations | 3 | 2021 | 171 | 0.470 |
Why?
| | Heating | 1 | 2015 | 18 | 0.450 |
Why?
| | Stress, Mechanical | 8 | 2026 | 494 | 0.450 |
Why?
| | Sciuridae | 1 | 2017 | 152 | 0.450 |
Why?
| | Hemorrhage | 2 | 2019 | 822 | 0.450 |
Why?
| | Bleeding Time | 1 | 2015 | 5 | 0.440 |
Why?
| | Ferric Compounds | 1 | 2015 | 54 | 0.440 |
Why?
| | Humans | 56 | 2026 | 145750 | 0.440 |
Why?
| | Protein Aggregates | 1 | 2015 | 85 | 0.430 |
Why?
| | Saphenous Vein | 1 | 2015 | 37 | 0.430 |
Why?
| | Water Pollutants, Chemical | 1 | 2018 | 227 | 0.430 |
Why?
| | Chlorides | 1 | 2015 | 138 | 0.420 |
Why?
| | Cell Adhesion | 3 | 2014 | 451 | 0.420 |
Why?
| | Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2018 | 25 | 0.420 |
Why?
| | Lipoproteins | 2 | 2026 | 166 | 0.410 |
Why?
| | Metabolic Flux Analysis | 2 | 2025 | 8 | 0.400 |
Why?
| | Models, Cardiovascular | 3 | 2026 | 196 | 0.390 |
Why?
| | Polymers | 4 | 2015 | 485 | 0.370 |
Why?
| | Epigastric Arteries | 1 | 2012 | 33 | 0.370 |
Why?
| | Animals | 34 | 2026 | 38100 | 0.370 |
Why?
| | Femoral Vein | 1 | 2012 | 38 | 0.370 |
Why?
| | Arterial Occlusive Diseases | 1 | 2012 | 90 | 0.360 |
Why?
| | Collagen Type I | 1 | 2013 | 143 | 0.360 |
Why?
| | Extracellular Fluid | 2 | 2013 | 38 | 0.360 |
Why?
| | E-Selectin | 1 | 2012 | 61 | 0.350 |
Why?
| | Nanotubes | 1 | 2012 | 46 | 0.350 |
Why?
| | Carotid Arteries | 1 | 2012 | 208 | 0.340 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2012 | 81 | 0.340 |
Why?
| | Fibrin Clot Lysis Time | 2 | 2021 | 10 | 0.330 |
Why?
| | Cell Separation | 1 | 2012 | 306 | 0.330 |
Why?
| | Vascular Diseases | 1 | 2013 | 252 | 0.320 |
Why?
| | Hemodynamics | 4 | 2018 | 1118 | 0.310 |
Why?
| | Biophysics | 1 | 2010 | 75 | 0.300 |
Why?
| | Blood Flow Velocity | 4 | 2018 | 421 | 0.290 |
Why?
| | Computer Simulation | 4 | 2026 | 1003 | 0.290 |
Why?
| | Groundwater | 2 | 2020 | 40 | 0.290 |
Why?
| | Endothelial Cells | 1 | 2015 | 877 | 0.290 |
Why?
| | Receptors, Thrombin | 1 | 2008 | 13 | 0.280 |
Why?
| | Kinetics | 5 | 2018 | 1568 | 0.270 |
Why?
| | Nitric Oxide | 1 | 2013 | 892 | 0.270 |
Why?
| | Platelet Function Tests | 3 | 2021 | 35 | 0.270 |
Why?
| | Adenosine Diphosphate | 1 | 2008 | 83 | 0.270 |
Why?
| | Membranes, Artificial | 1 | 2008 | 68 | 0.270 |
Why?
| | Pulmonary Embolism | 2 | 2022 | 241 | 0.260 |
Why?
| | Porosity | 3 | 2020 | 94 | 0.260 |
Why?
| | Neostriatum | 1 | 2007 | 37 | 0.260 |
Why?
| | Dilatation | 1 | 2007 | 73 | 0.250 |
Why?
| | Shear Strength | 5 | 2026 | 73 | 0.240 |
Why?
| | Protein S | 1 | 2026 | 10 | 0.240 |
Why?
| | Qc-SNARE Proteins | 1 | 2026 | 8 | 0.240 |
Why?
| | Qb-SNARE Proteins | 1 | 2026 | 7 | 0.240 |
Why?
| | Pyruvate Kinase | 1 | 2026 | 29 | 0.230 |
Why?
| | Extracellular Traps | 1 | 2026 | 52 | 0.230 |
Why?
| | Biological Transport | 3 | 2017 | 424 | 0.220 |
Why?
| | Exocytosis | 1 | 2026 | 85 | 0.220 |
Why?
| | Adventitia | 1 | 2025 | 42 | 0.220 |
Why?
| | Silicon Dioxide | 2 | 2018 | 119 | 0.220 |
Why?
| | Equipment Design | 6 | 2016 | 525 | 0.210 |
Why?
| | Hydrodynamics | 5 | 2019 | 50 | 0.210 |
Why?
| | Stroke | 2 | 2024 | 1271 | 0.210 |
Why?
| | Extracellular Matrix | 2 | 2011 | 562 | 0.210 |
Why?
| | Microscopy, Electron, Scanning | 3 | 2014 | 196 | 0.200 |
Why?
| | von Willebrand Diseases | 1 | 2023 | 28 | 0.190 |
Why?
| | Gels | 2 | 2015 | 85 | 0.180 |
Why?
| | Leukocyte Elastase | 1 | 2022 | 75 | 0.180 |
Why?
| | Estrogens | 1 | 2025 | 367 | 0.180 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2022 | 61 | 0.180 |
Why?
| | Models, Theoretical | 3 | 2019 | 560 | 0.170 |
Why?
| | Hematocrit | 2 | 2018 | 108 | 0.160 |
Why?
| | Recombinant Proteins | 1 | 2024 | 1368 | 0.160 |
Why?
| | Respiratory Mucosa | 2 | 2014 | 322 | 0.160 |
Why?
| | Mice | 14 | 2026 | 18357 | 0.160 |
Why?
| | High-Energy Shock Waves | 1 | 2019 | 4 | 0.150 |
Why?
| | Blood Coagulation Tests | 2 | 2021 | 72 | 0.150 |
Why?
| | Magnetite Nanoparticles | 1 | 2019 | 27 | 0.150 |
Why?
| | ADAMTS13 Protein | 1 | 2019 | 7 | 0.150 |
Why?
| | Fibroblasts | 1 | 2025 | 1027 | 0.150 |
Why?
| | Convection | 3 | 2011 | 7 | 0.150 |
Why?
| | Semaphorins | 2 | 2010 | 37 | 0.150 |
Why?
| | Herpes Zoster | 1 | 2023 | 319 | 0.150 |
Why?
| | Pulmonary Artery | 1 | 2025 | 1129 | 0.140 |
Why?
| | Drug Compounding | 1 | 2019 | 107 | 0.140 |
Why?
| | Case-Control Studies | 2 | 2024 | 3634 | 0.140 |
Why?
| | Microelectrodes | 3 | 2007 | 49 | 0.140 |
Why?
| | Robotics | 1 | 2019 | 90 | 0.140 |
Why?
| | Male | 19 | 2025 | 72992 | 0.130 |
Why?
| | Geologic Sediments | 1 | 2018 | 46 | 0.130 |
Why?
| | von Willebrand Disease, Type 1 | 1 | 2017 | 5 | 0.130 |
Why?
| | Phosphatidylserines | 1 | 2018 | 62 | 0.130 |
Why?
| | Hemorheology | 1 | 2017 | 24 | 0.130 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2018 | 39 | 0.130 |
Why?
| | Viscosity | 2 | 2015 | 92 | 0.130 |
Why?
| | Liposomes | 1 | 2019 | 263 | 0.130 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 192 | 0.130 |
Why?
| | Antithrombin III | 1 | 2017 | 18 | 0.130 |
Why?
| | Thromboxane A2 | 1 | 2016 | 9 | 0.130 |
Why?
| | Magnetics | 1 | 2017 | 46 | 0.130 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2016 | 6 | 0.130 |
Why?
| | Flow Cytometry | 3 | 2016 | 1165 | 0.130 |
Why?
| | Cells, Cultured | 4 | 2025 | 4151 | 0.120 |
Why?
| | Antibodies, Monoclonal | 1 | 2024 | 1505 | 0.120 |
Why?
| | Adsorption | 2 | 2020 | 153 | 0.120 |
Why?
| | Antigens, CD | 2 | 2010 | 558 | 0.120 |
Why?
| | Protein Binding | 3 | 2026 | 2240 | 0.120 |
Why?
| | Platelet Aggregation Inhibitors | 2 | 2018 | 499 | 0.120 |
Why?
| | Peptide Hydrolases | 1 | 2017 | 105 | 0.120 |
Why?
| | Blood Cells | 1 | 2015 | 38 | 0.120 |
Why?
| | Models, Molecular | 1 | 2021 | 1599 | 0.110 |
Why?
| | Disease Models, Animal | 5 | 2026 | 4569 | 0.110 |
Why?
| | Models, Anatomic | 1 | 2016 | 87 | 0.110 |
Why?
| | Adenine | 1 | 2018 | 339 | 0.110 |
Why?
| | Clot Retraction | 1 | 2015 | 2 | 0.110 |
Why?
| | Piperazines | 1 | 2018 | 375 | 0.110 |
Why?
| | Arteries | 1 | 2017 | 261 | 0.110 |
Why?
| | Electrodes | 1 | 2015 | 111 | 0.110 |
Why?
| | Time Factors | 4 | 2017 | 7133 | 0.110 |
Why?
| | Pneumonia | 1 | 2020 | 636 | 0.110 |
Why?
| | Blood Vessels | 1 | 2016 | 167 | 0.110 |
Why?
| | Elastic Modulus | 1 | 2015 | 121 | 0.110 |
Why?
| | Nanotechnology | 2 | 2013 | 114 | 0.100 |
Why?
| | Bioreactors | 1 | 2014 | 50 | 0.100 |
Why?
| | Enzyme Precursors | 1 | 2014 | 15 | 0.100 |
Why?
| | Toxicity Tests | 1 | 2014 | 53 | 0.100 |
Why?
| | Temperature | 1 | 2017 | 633 | 0.100 |
Why?
| | Signal Transduction | 4 | 2018 | 5223 | 0.100 |
Why?
| | Microscopy, Confocal | 1 | 2015 | 319 | 0.100 |
Why?
| | Rats | 5 | 2014 | 5585 | 0.100 |
Why?
| | Models, Chemical | 1 | 2015 | 250 | 0.100 |
Why?
| | Cysteine Endopeptidases | 1 | 2013 | 78 | 0.100 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2014 | 92 | 0.100 |
Why?
| | Rats, Sprague-Dawley | 3 | 2011 | 2525 | 0.100 |
Why?
| | Bronchi | 2 | 2012 | 263 | 0.100 |
Why?
| | Materials Testing | 1 | 2015 | 345 | 0.100 |
Why?
| | Surface Properties | 2 | 2019 | 386 | 0.100 |
Why?
| | Optical Tweezers | 1 | 2013 | 21 | 0.100 |
Why?
| | Azo Compounds | 1 | 2013 | 30 | 0.100 |
Why?
| | International Cooperation | 1 | 2014 | 197 | 0.100 |
Why?
| | Hypoxia | 1 | 2020 | 1199 | 0.100 |
Why?
| | Receptor, PAR-2 | 1 | 2012 | 6 | 0.090 |
Why?
| | Lipid Bilayers | 1 | 2014 | 103 | 0.090 |
Why?
| | Factor VII | 1 | 2012 | 24 | 0.090 |
Why?
| | Receptor, PAR-1 | 1 | 2012 | 17 | 0.090 |
Why?
| | Fibrillar Collagens | 1 | 2012 | 14 | 0.090 |
Why?
| | Permeability | 1 | 2013 | 169 | 0.090 |
Why?
| | Polymerization | 1 | 2013 | 127 | 0.090 |
Why?
| | Spectrophotometry | 1 | 2012 | 58 | 0.090 |
Why?
| | Linear Models | 1 | 2015 | 849 | 0.090 |
Why?
| | Microvilli | 1 | 2012 | 75 | 0.090 |
Why?
| | Microscopy, Fluorescence | 1 | 2014 | 408 | 0.090 |
Why?
| | Biomechanical Phenomena | 2 | 2013 | 860 | 0.090 |
Why?
| | Observer Variation | 1 | 2013 | 357 | 0.090 |
Why?
| | Polystyrenes | 2 | 2011 | 38 | 0.090 |
Why?
| | Horses | 1 | 2013 | 226 | 0.090 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 375 | 0.090 |
Why?
| | Microscopy, Fluorescence, Multiphoton | 1 | 2011 | 63 | 0.080 |
Why?
| | Surface Plasmon Resonance | 1 | 2011 | 87 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 981 | 0.080 |
Why?
| | Blood Coagulation Disorders | 1 | 2013 | 198 | 0.080 |
Why?
| | Microscopy, Atomic Force | 1 | 2011 | 128 | 0.080 |
Why?
| | Cell Membrane | 2 | 2015 | 709 | 0.080 |
Why?
| | Female | 11 | 2025 | 79025 | 0.080 |
Why?
| | Ozone | 1 | 2011 | 116 | 0.080 |
Why?
| | Neoplasm Proteins | 1 | 2013 | 442 | 0.080 |
Why?
| | Epithelial Cells | 2 | 2014 | 1134 | 0.080 |
Why?
| | Platelet Factor 4 | 2 | 2020 | 36 | 0.080 |
Why?
| | Lung | 2 | 2020 | 4116 | 0.080 |
Why?
| | Integrins | 1 | 2010 | 90 | 0.080 |
Why?
| | Mice, Knockout | 4 | 2026 | 3130 | 0.080 |
Why?
| | Myocytes, Cardiac | 1 | 2014 | 546 | 0.070 |
Why?
| | Societies, Medical | 1 | 2014 | 900 | 0.070 |
Why?
| | Absorbable Implants | 1 | 2009 | 38 | 0.070 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2014 | 782 | 0.070 |
Why?
| | Brain Diseases | 1 | 2010 | 155 | 0.070 |
Why?
| | src-Family Kinases | 1 | 2009 | 92 | 0.070 |
Why?
| | Integrin alpha2beta1 | 1 | 2008 | 3 | 0.070 |
Why?
| | Reproducibility of Results | 2 | 2016 | 3416 | 0.070 |
Why?
| | Water | 1 | 2011 | 447 | 0.070 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1957 | 0.070 |
Why?
| | Dimethylpolysiloxanes | 1 | 2008 | 9 | 0.070 |
Why?
| | Hyperlipidemias | 1 | 2009 | 120 | 0.070 |
Why?
| | Silicones | 1 | 2008 | 31 | 0.070 |
Why?
| | Cerebral Cortex | 1 | 2011 | 474 | 0.070 |
Why?
| | Cell Membrane Permeability | 1 | 2008 | 88 | 0.070 |
Why?
| | Hyaluronoglucosaminidase | 1 | 2007 | 7 | 0.070 |
Why?
| | Protein Array Analysis | 1 | 2008 | 56 | 0.070 |
Why?
| | Electrodes, Implanted | 2 | 2006 | 114 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2010 | 457 | 0.060 |
Why?
| | Osmolar Concentration | 1 | 2007 | 168 | 0.060 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2010 | 431 | 0.060 |
Why?
| | Molecular Weight | 1 | 2007 | 312 | 0.060 |
Why?
| | Tissue Distribution | 1 | 2007 | 335 | 0.060 |
Why?
| | Reference Values | 1 | 2008 | 798 | 0.060 |
Why?
| | Evans Blue | 1 | 2006 | 8 | 0.060 |
Why?
| | Caudate Nucleus | 1 | 2006 | 22 | 0.060 |
Why?
| | Insecta | 1 | 2006 | 71 | 0.060 |
Why?
| | Algorithms | 2 | 2011 | 1850 | 0.060 |
Why?
| | Diffusion | 1 | 2006 | 120 | 0.060 |
Why?
| | Extremities | 1 | 2006 | 142 | 0.060 |
Why?
| | Albumins | 1 | 2006 | 119 | 0.060 |
Why?
| | Muscles | 1 | 2006 | 330 | 0.060 |
Why?
| | Phenotype | 1 | 2013 | 3170 | 0.060 |
Why?
| | Atherosclerosis | 1 | 2009 | 409 | 0.050 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 428 | 0.050 |
Why?
| | Infusion Pumps, Implantable | 1 | 2004 | 26 | 0.050 |
Why?
| | Brain | 2 | 2009 | 2969 | 0.050 |
Why?
| | Foreign-Body Reaction | 1 | 2004 | 34 | 0.050 |
Why?
| | Movement | 2 | 2017 | 293 | 0.050 |
Why?
| | Immunoblotting | 2 | 2016 | 295 | 0.050 |
Why?
| | Elasticity | 2 | 2015 | 189 | 0.050 |
Why?
| | Sensitivity and Specificity | 1 | 2008 | 2000 | 0.050 |
Why?
| | Anticoagulants | 2 | 2021 | 748 | 0.050 |
Why?
| | Electric Impedance | 2 | 2014 | 108 | 0.050 |
Why?
| | P-Selectin | 1 | 2022 | 29 | 0.050 |
Why?
| | CD36 Antigens | 1 | 2022 | 32 | 0.050 |
Why?
| | Child, Preschool | 2 | 2017 | 11866 | 0.050 |
Why?
| | Mammals | 1 | 2024 | 286 | 0.050 |
Why?
| | Apolipoprotein A-I | 1 | 2022 | 39 | 0.050 |
Why?
| | Arachidonic Acid | 1 | 2022 | 102 | 0.040 |
Why?
| | Exosomes | 1 | 2023 | 104 | 0.040 |
Why?
| | Pentose Phosphate Pathway | 1 | 2021 | 55 | 0.040 |
Why?
| | Hydroxychloroquine | 1 | 2022 | 65 | 0.040 |
Why?
| | Blood Specimen Collection | 1 | 2021 | 37 | 0.040 |
Why?
| | Cystic Fibrosis | 1 | 2011 | 1163 | 0.040 |
Why?
| | Plasma | 1 | 2023 | 223 | 0.040 |
Why?
| | Computational Biology | 1 | 2026 | 669 | 0.040 |
Why?
| | Blood Pressure | 1 | 2008 | 1782 | 0.040 |
Why?
| | Brain Neoplasms | 1 | 2010 | 1331 | 0.040 |
Why?
| | Chemokine CCL5 | 1 | 2020 | 40 | 0.040 |
Why?
| | Young Adult | 2 | 2017 | 14250 | 0.040 |
Why?
| | Factor Xa | 1 | 2020 | 36 | 0.040 |
Why?
| | Carbon | 1 | 2021 | 176 | 0.040 |
Why?
| | Binding, Competitive | 1 | 2020 | 185 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2020 | 118 | 0.040 |
Why?
| | Phosphorylation | 2 | 2018 | 1708 | 0.040 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 5992 | 0.040 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2020 | 18 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2022 | 440 | 0.040 |
Why?
| | Glycolysis | 1 | 2021 | 340 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 161 | 0.040 |
Why?
| | Research | 1 | 2023 | 431 | 0.040 |
Why?
| | Sex Characteristics | 1 | 2025 | 789 | 0.040 |
Why?
| | Herpesvirus 3, Human | 1 | 2023 | 343 | 0.040 |
Why?
| | Zebrafish | 1 | 2024 | 532 | 0.040 |
Why?
| | Catheterization | 2 | 2010 | 184 | 0.040 |
Why?
| | Motion | 1 | 2019 | 95 | 0.040 |
Why?
| | Rotation | 1 | 2019 | 121 | 0.040 |
Why?
| | Thrombocytopenia | 1 | 2020 | 204 | 0.040 |
Why?
| | Bleomycin | 1 | 2020 | 255 | 0.030 |
Why?
| | Adolescent | 2 | 2017 | 22569 | 0.030 |
Why?
| | Hydrogels | 1 | 2025 | 701 | 0.030 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2017 | 15 | 0.030 |
Why?
| | Serotonin | 1 | 2020 | 298 | 0.030 |
Why?
| | Uncertainty | 1 | 2018 | 146 | 0.030 |
Why?
| | Purinergic P2Y Receptor Antagonists | 1 | 2018 | 71 | 0.030 |
Why?
| | Adult | 3 | 2019 | 40867 | 0.030 |
Why?
| | Animals, Newborn | 1 | 2020 | 896 | 0.030 |
Why?
| | Drug Synergism | 1 | 2018 | 354 | 0.030 |
Why?
| | Hemostatics | 1 | 2017 | 64 | 0.030 |
Why?
| | Cytoplasmic Granules | 1 | 2016 | 60 | 0.030 |
Why?
| | Neutrophils | 1 | 2022 | 1125 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2018 | 376 | 0.030 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2018 | 231 | 0.030 |
Why?
| | Down-Regulation | 1 | 2017 | 618 | 0.030 |
Why?
| | Miniaturization | 1 | 2015 | 22 | 0.030 |
Why?
| | Blood Circulation | 1 | 2015 | 44 | 0.030 |
Why?
| | Thrombopoiesis | 1 | 2014 | 7 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 1044 | 0.030 |
Why?
| | Megakaryocytes | 1 | 2014 | 34 | 0.030 |
Why?
| | Nanostructures | 1 | 2016 | 105 | 0.030 |
Why?
| | Machine Learning | 1 | 2020 | 587 | 0.030 |
Why?
| | Proto-Oncogene Proteins | 1 | 2018 | 625 | 0.030 |
Why?
| | Chlorine | 1 | 2014 | 59 | 0.030 |
Why?
| | Platelet Transfusion | 1 | 2014 | 77 | 0.020 |
Why?
| | Biomimetic Materials | 1 | 2014 | 78 | 0.020 |
Why?
| | Inhalation Exposure | 1 | 2014 | 103 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 2017 | 1512 | 0.020 |
Why?
| | Risk Assessment | 1 | 2023 | 3752 | 0.020 |
Why?
| | Erythrocyte Deformability | 1 | 2013 | 23 | 0.020 |
Why?
| | Gases | 1 | 2013 | 46 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2014 | 571 | 0.020 |
Why?
| | Nitrogen | 1 | 2013 | 125 | 0.020 |
Why?
| | Pressure | 1 | 2013 | 226 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 2123 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 334 | 0.020 |
Why?
| | Serum Albumin, Bovine | 1 | 2011 | 62 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2015 | 401 | 0.020 |
Why?
| | Cell Death | 1 | 2012 | 382 | 0.020 |
Why?
| | Microtechnology | 1 | 2010 | 8 | 0.020 |
Why?
| | Syk Kinase | 1 | 2010 | 19 | 0.020 |
Why?
| | Phospholipase C gamma | 1 | 2010 | 28 | 0.020 |
Why?
| | Trachea | 1 | 2012 | 258 | 0.020 |
Why?
| | Immunoprecipitation | 1 | 2010 | 149 | 0.020 |
Why?
| | Catheters | 1 | 2010 | 74 | 0.020 |
Why?
| | Particle Size | 1 | 2011 | 381 | 0.020 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 638 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2012 | 265 | 0.020 |
Why?
| | Wound Healing | 1 | 2012 | 355 | 0.020 |
Why?
| | Polyglactin 910 | 1 | 2009 | 6 | 0.020 |
Why?
| | Fluorescent Dyes | 1 | 2011 | 334 | 0.020 |
Why?
| | Diet, Atherogenic | 1 | 2009 | 6 | 0.020 |
Why?
| | Cell Survival | 1 | 2012 | 1103 | 0.020 |
Why?
| | Proline | 1 | 2009 | 82 | 0.020 |
Why?
| | Inflammation | 1 | 2020 | 2883 | 0.020 |
Why?
| | Platelet Glycoprotein GPIb-IX Complex | 1 | 2008 | 2 | 0.020 |
Why?
| | Factor XIIa | 1 | 2008 | 2 | 0.020 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 373 | 0.020 |
Why?
| | Plant Proteins | 1 | 2008 | 111 | 0.020 |
Why?
| | Amplifiers, Electronic | 1 | 2006 | 7 | 0.020 |
Why?
| | Cockroaches | 1 | 2006 | 23 | 0.020 |
Why?
| | Xylenes | 1 | 2006 | 8 | 0.020 |
Why?
| | Aorta, Thoracic | 1 | 2009 | 286 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4302 | 0.010 |
Why?
| | Electrophysiology | 1 | 2006 | 218 | 0.010 |
Why?
| | Middle Aged | 2 | 2019 | 36297 | 0.010 |
Why?
| | Locomotion | 1 | 2006 | 101 | 0.010 |
Why?
| | Transferrin | 1 | 2004 | 50 | 0.010 |
Why?
| | Calcium | 1 | 2010 | 1191 | 0.010 |
Why?
| | Equipment Failure | 1 | 2004 | 115 | 0.010 |
Why?
| | Running | 1 | 2006 | 233 | 0.010 |
Why?
| | Cytokines | 1 | 2011 | 2069 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 11793 | 0.010 |
Why?
| | Feasibility Studies | 1 | 2004 | 1115 | 0.010 |
Why?
| | Child | 1 | 2017 | 22738 | 0.010 |
Why?
| | Aged | 1 | 2017 | 26212 | 0.010 |
Why?
|
|
Neeves's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|